Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors / Victor Pérez en Journal of Clinical Psychopharmacology, Año 2001 - Vol. 21 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 36-45 Título : Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors Tipo de documento: texto impreso Autores: Victor Pérez, Autor ; Dolors Puigdemont, Autor ; Inmaculada Gilaberte, Autor Fecha de publicación: 2023 Artículo en la página: pp. 36-45 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Beta-Antagonistas adrenérgicos, Antidepresivos, Trastorno depresivo mayor, Farmacoterapia, Fluoxetina, Pindolol. Resumen: In a controlled trial, the β-adrenoceptor/5-hydroxytryptamine-1A (5-HT1A) receptor antagonist pindolol accelerated and enhanced the antidepressant effect of fluoxetine. The median times to sustained response (≥50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01). Link: ./index.php?lvl=notice_display&id=31135 [artículo] Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors [texto impreso] / Victor Pérez, Autor ; Dolors Puigdemont, Autor ; Inmaculada Gilaberte, Autor . - 2023 . - pp. 36-45. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 36-45 Palabras clave: Beta-Antagonistas adrenérgicos, Antidepresivos, Trastorno depresivo mayor, Farmacoterapia, Fluoxetina, Pindolol. Resumen: In a controlled trial, the β-adrenoceptor/5-hydroxytryptamine-1A (5-HT1A) receptor antagonist pindolol accelerated and enhanced the antidepressant effect of fluoxetine. The median times to sustained response (≥50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01). Link: ./index.php?lvl=notice_display&id=31135

---

1 (1 - 1 / 1)